Company / PP&E (Net)
Intellia Therapeutics, Inc. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$17.7M
FY2025
5-year range
$17.7M / $32.8M
FY2021-FY2025
Trend
-35.5%
vs FY2024
Sector context
#116 of 135
Health Care
What the data says
Intellia Therapeutics, Inc.'s pp&e (net) of $18M is lower than 86% of companies in the Health Care sector (FY2025). PP&E (Net) has fluctuated over the past 10 years, ranging from $11M in FY2016 to $33M in FY2023.
Based on SEC 10-K filings.
$18M in FY2025 with a 5-year CAGR of +2.1%.
Declined from $33M to $18M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -14.1%
- 5-Year CAGR
- +2.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 14% in Health CareTop 86% of 135This company $17.7M Sector average $1.4B
▼
-98.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +2.1%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 35.5% year-over-year.
- Ranks #116 out of 135 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $17.7M | -35.5% |
| FY2024 | $27.4M | -16.4% |
| FY2023 | $32.8M | +17.3% |
| FY2022 | $27.9M | +33.2% |
| FY2021 | $21.0M | +31.5% |
| FY2020 | $15.9M | -11.4% |
| FY2019 | $18.0M | +5.5% |
| FY2018 | $17.1M | +11.7% |
| FY2017 | $15.3M | +43.7% |
| FY2016 | $10.6M | +292.5% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026